BioSpace News Archive

Drug Development

CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment

CEL-SCI Corporation (NYSE American: CVM) today announced the availability to the public of an oral presentation delivered by Dr. Philip Lavin of groundbreaking tumor response and increased overall survival in head and neck cancer.

October 17, 2022
·
7 min read
Business

Exagen Announces Appointment of John Aballi as CEO

Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John Aballi as CEO and President. Longtime CEO and President Ron Rocca, who took the company public and built a robust growth business, is stepping down after 11 years at the helm.

October 17, 2022
·
5 min read
Bio NC

Biohope and C. Alan Foundation Named Winners of the 2022 Lyfebulb-Veloxis Innovation Challenge: Transforming Organ Transplantation

Lyfebulb and Veloxis Pharmaceuticals are excited to announce that Biohope was selected as the winner of the Innovation Award and C. Alan Foundation as the winner of the Impact Award at the 2022 Lyfebulb-Veloxis Innovation Challenge: Transforming Organ Transplantation.

October 17, 2022
·
4 min read
Policy

FDA Awards 19 Grants and Two Contracts Related to Rare Diseases, including ALS

The U.S. Food and Drug Administration announced it has awarded 19 new grants and two new contracts totaling more than $38 million in funding over the next four years to support clinical trials, natural history studies and regulatory science tools related to rare diseases.

October 17, 2022
·
5 min read
SpectronRx Completes Critical Step in Path to Supplying Europe With Life-Saving Radiopharmaceuticals

Indiana-based radiopharmaceutical developer and manufacturer completes FDA inspection on behalf of the European Medicines Agency (EMA)

October 17, 2022
·
3 min read
Pharm Country

New Biotechnology Combines Targeted and Immune Therapies to Kill Treatment-resistant Cancer Cells

Targeted therapies specifically attach to and hinder cancer-causing proteins, but cancer cells can quickly evolve to thwart their action.

October 17, 2022
·
6 min read
Active Pharmaceutical Ingredients Market Size to Hit USD 354.1 Bn by 2030

According to Nova one advisor, the global Active Pharmaceutical Ingredient market size is expected to hit around USD 354.1 billion by 2030 from valued at USD 209.9 billion in 2021 and growing at a CAGR of 7.2% from 2022 to 2030.

October 17, 2022
·
7 min read
Business

PerkinElmer to Hold Earnings Call on Tuesday, November 8, 2022; Updates Third Quarter Outlook

PerkinElmer, Inc. today announced it will release its full third quarter 2022 financial results on November 8, 2022.

October 17, 2022
·
3 min read
Business

Evotec and TIAP Expand LAB150 BRIDGE Partnership to Include Amgen

Evotec SE and Toronto Innovation Acceleration Partners today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner.

October 17, 2022
·
7 min read
Genetown

Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen

Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the new drug application (NDA) for tofersen by three months.

October 17, 2022
·
7 min read